Anal Cancer Market Size
| Study Period | 2018-2029 |
| Market Size (2024) | USD 0.91 Billion |
| Market Size (2029) | USD 1.26 Billion |
| CAGR (2024 - 2029) | 6.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Anal Cancer Market Analysis
The Anal Cancer Market size is estimated at USD 0.91 billion in 2024, and is expected to reach USD 1.26 billion by 2029, growing at a CAGR of 6.60% during the forecast period (2024-2029).
The COVID-19 pandemic influenced the anal cancer market through supply chain disruptions that hindered the manufacture and distribution of medical products required for anal cancer treatment. Due to the global pandemic, the healthcare staff put more effort into combating the infections, and other medical procedures and cancer screening were declined. For instance, in August 2023, an article published in the eClinical Medicine Journal estimated that COVID-19-related screening resulted in the loss of around 7.4 million lower fecal screenings in colorectal cancer during the beginning of the pandemic. Thus, the decline in anal cancer screening affected the diagnosis and treatment of anal cancer, hence impacted the market during the pandemic. There was a significant risk of anal cancer in individuals with COVID-19 infection and other cancers. Thus, due to the high risk of anal cancer development and progression with COVID-19 infection and other comorbidities contributed to the market growth.
Various factors, such as the incidence of anal cancer, the increase in the prevalence of sexually transmitted diseases and anal cancer, and the rise in research and development activities, will lead to market growth during the forecast period.
The increase in the incidence of anal cancer and the prevalence of sexually transmitted infections and anal cancer is the primary factor influencing the market growth. Anal cancer is caused by the human papillomavirus due to skin-to-skin contact of the genital organs, resulting in a sexually transmitted disease. For instance, Cancer Research UK published statistics reported that anal cancer incidence rates are projected to grow by 14% in the United Kingdom between 2023-2025 and 2038-2040, and there are approximately 2,400 new cases of anal cancer every year in the United Kingdom by 2038-2040. Additionally, anal cancer is predominantly found in females as compared with males. Thus, the growing incidence rate of anal cancer is a significant factor boosting the market growth over the forecast period.
Moreover, the increase in research and development activities for the production of effective treatments to treat anal cancer is contributing significantly to the market growth. For instance, in July 2022, the Anal Cancer Foundation published an Anal Cancer high-grade squamous intraepithelial lesion (HSIL) Outcomes Research (ANCHOR) study in the New England Journal of Medicine, represented that early detection and treatment of anal HSIL (anal precancer) can decrease disease progression by 57%. Additionally, the study found that the incidence rate of anal cancer was higher in the patients infected with the human immune-deficiency virus (HIV). Moreover, partnerships of research institutes promote the treatment development of anal cancer. For instance, in September 2023, the University of Cincinnati Cancer Center Research established a partnership with Ride Cincinnati (an organization involved in cancer research and care), which raised funding of USD 4 million for the treatment of patients with anal cancer and improving the quality of life of patients. Thus, increased research activities to determine the causes and effective treatments contributed to the market growth.
Hence, the increase in the prevalence of sexually transmitted infections will contribute to the rise in anal cancer cases, and the increase in research and development activities with significant funding are the major factors driving the market growth. However, the side effects of chemotherapy and the high cost of treatments may affect the market growth of anal cancer over the forecast period.
Anal Cancer Market Trends
Chemotherapy Treatment Segment is Witnessed to Hold the Highest Share During the Forecast Period.
The chemotherapy treatment segment is expected to contribute the highest share of the market growth. Chemotherapy treatment is advantageous for decreasing the cancer cell counts in the body and reducing the progression of the disease with shrinkage in tumors. Adjuvant chemotherapy is chemotherapy that is provided post-surgical procedure or radiation therapy to reduce the tumor cell size, and neo-adjuvant chemotherapy is given to the patients before the surgery and radiation therapy. For instance, in August 2022, a study published in the Journal of Current Treatment Options in Oncology reported that palliative chemotherapy was effective for the management of squamous cell carcinoma of the anal canal with a response rate of 60%. The study involved the use of carboplatin with paclitaxel and modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line therapy to provide promising results to the patients. Therefore, owing to the potential benefits of chemotherapy treatment for minimizing the impact of anal cancer is contributing to the market growth.
Moreover, clinical trials are conducted by the market players for the development of treatment of anal cancer. For instance, in March 2023, Incyte introduced Zynyz (retifanlimab-dlwr) for Merkel Cell Carcinoma and continued to conduct the POD1UM (PD-1 clinical program in multiple malignancies) clinical trial for evaluating the retifanlimab as a monotherapy for patients with squamous cell carcinoma of the anal canal (SCAC). Further, in June 2023, the Memorial Sloan Kettering Cancer Center published the research results in The New England Journal of Medicine, stating that a chemotherapy regimen known as FOLFOX alone before surgery was effective and showed the same results for patients who underwent both chemotherapy and radiation before surgery. Thus, radiation can be skipped to improve patients' quality of life, and chemotherapy is adopted by oncologists, contributing to the market growth.
North America is Anticipated to Occupy the Highest Share During the Forecast Period.
North America is dominating the market and is expected to contribute the same over the forecast period. This is due to the growing burden of anal cancer cases, the increase in research activities, and government initiatives for the development of anal cancer treatments. The growing burden of anal cancer in North America is influencing the market growth. For instance, in March 2023, according to the statistics published by the American Society of Clinical Oncology, estimated that 9,760 adults (3,180 males and 6,580 females) will be diagnosed with anal cancer in the United States in 2023. These estimates show that females are more likely to be diagnosed with anal cancer. Thus, the increasing prevalence of anal cancer among adults in North America contributes to the market growth.
Moreover, research institutes are highly involved in clinical trials for anal cancer therapy development. For instance, in 2023, Mayo Clinic conducted a clinical trial for Nivolumab, which can be given after combined modality therapy for the treatment of patients with high-risk stage II-IIIB anal cancer. Monoclonal antibodies, such as Nivolumab, can decline the spread and growth of cancerous cells, thus being effective in reducing the anal cancer burden. Further, in November 2023, Oncolytics Biotech Inc. introduced the interim results from the Phase 1/2 GOBLET study to determine the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA). The results fulfilled the pre-specified requirements for the cohort and exceeded the results from historical controls in similar patient populations.
Furthermore, the significant collaborations and initiatives led by the government to fight against anal cancer influenced the market growth of anal cancer. For instance, in August 2023, Fight Colorectal Cancer collaborated with the National Comprehensive Cancer Network and Pfizer Inc. to optimize biomarker-directed therapy for the treatment of colorectal cancer. Thus, multiple clinical studies and collaborations are conducted to launch new drugs in the market for anal cancer treatment, significantly contributing to the market growth.
Anal Cancer Industry Overview
The anal cancer market is moderately fragmented because of the presence of large and mid-sized companies contributing to the market share. The market players are adopting various approaches comprising mergers and acquisitions, partnerships, and new product launches. The companies make substantial investments and integration of advanced technologies to expand production and maximize the product portfolio of drugs. Some prominent players are Amgen Inc., Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, and F. Hoffman La Roche Ltd., among others.
Anal Cancer Market Leaders
Amgen Inc.
Bristol Myers Squibb
Celgene Corporation
Eli Lilly and Company
F. Hoffman La Roche Ltd.
*Disclaimer: Major Players sorted in no particular order
Anal Cancer Market News
- June 2023: AstraZeneca and Daiichi Sankyo represented positive results from the clinical study of the DESTINY CRC02 phase trial for Enhertu, comprising effectiveness and safety in patients with previously treated HER-2 positive metastatic colorectal cancer.
- January 2023: Seagen Inc. received the United States Food and Drug Administration approval for TUKYSA (tucatinib) in combination with trastuzumab for adult patients with RASwild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
Anal Cancer Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Sexually Transmitted Diseases and Anal Cancer
4.2.2 Increase in Research and Development
4.3 Market Restraints
4.3.1 Side Effects and High Cost of Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Cancer Type
5.1.1 Carcinoma In-Situ
5.1.2 Squamous Cell Carcinoma
5.1.3 Melanoma
5.1.4 Adenocarcinoma
5.1.5 Basal Cell Carcinoma
5.1.6 Other Cancer Types
5.2 By Treatment Type
5.2.1 Chemotherapy
5.2.2 Surgery
5.2.3 Radiation Therapy
5.2.4 Immunotherapy
5.3 By End-User
5.3.1 Hospitals and Clinics
5.3.2 Research and Academic Institutes
5.3.3 Other End-Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 Bristol Myers Squibb
6.1.3 Celgene Corporation
6.1.4 Eli Lilly and Company
6.1.5 F. Hoffman La Roche Ltd.
6.1.6 Merck & Co. Inc.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 GlaxoSmithKline Plc.
6.1.10 Sanofi
6.1.11 Johnson & Johnson
6.1.12 Abbvie
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Anal Cancer Industry Segmentation
According to the scope, anal cancer is an abnormal growth of cells in or around the anus or anal canal.
The anal cancer market is segmented by cancer type (carcinoma in situ, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, and other cancer types), treatment type (chemotherapy, surgery, radiation therapy, and immunotherapy), end-users (hospitals and clinics, research and academic institutes, and other end-users) and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers a value of USD for the above segments.
Anal Cancer Market Research FAQs
How big is the Anal Cancer Market?
The Anal Cancer Market size is expected to reach USD 0.91 billion in 2024 and grow at a CAGR of 6.60% to reach USD 1.26 billion by 2029.
What is the current Anal Cancer Market size?
In 2024, the Anal Cancer Market size is expected to reach USD 0.91 billion.
Who are the key players in Anal Cancer Market?
Amgen Inc., Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company and F. Hoffman La Roche Ltd. are the major companies operating in the Anal Cancer Market.
Which is the fastest growing region in Anal Cancer Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2029).
Which region has the biggest share in Anal Cancer Market?
In 2023, the North America accounts for the largest market share in Anal Cancer Market.
What years does this Anal Cancer Market cover, and what was the market size in 2023?
In 2023, the Anal Cancer Market size was estimated at USD 0.85 billion. The report covers the Anal Cancer Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Anal Cancer Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Anal Cancer Industry Report
Statistics for the 2024 Anal Cancer market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Anal Cancer analysis includes a market forecast outlook to for 2024 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
